Price
$1.24
Decreased by -3.88%
Dollar volume (20D)
73.19 K
ADR%
17.85
Earnings report date
Mar 25, 2025
Shares float
35.89 M
Shares short
31.39 K [0.09%]
Shares outstanding
5.58 M
Market cap
13.28 M
Beta
-0.23
Price/earnings
N/A
20D range
1.19 2.34
50D range
1.19 3.13
200D range
1.19 4.41

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.

The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.

Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.

Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Oct 31, 24 -0.04
Increased by +80.95%
-0.31
Increased by +87.10%
Aug 14, 24 -0.12
Increased by +42.86%
-0.39
Increased by +69.23%
May 28, 24 0.30
Increased by +225.00%
-0.56
Increased by +153.57%
Mar 26, 24 -1.60
Increased by +44.83%
-1.60
Dec 19, 23 -0.21
Increased by +12.50%
-0.19
Decreased by -10.53%
Aug 18, 23 -0.21
Decreased by -5.00%
-0.21
May 31, 23 -0.24
Increased by +4.00%
-0.24
Dec 31, 22 -2.90
Decreased by -643.59%
-2.63
Decreased by -10.27%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 3.03 M
Increased by +N/A%
-1.94 M
Increased by +65.81%
Decreased by -64.14%
Decreased by N/A%
Jun 30, 24 153.89 K
Increased by +N/A%
-6.19 M
Decreased by -9.08%
Decreased by -4.02 K%
Decreased by N/A%
Mar 31, 24 50.88 K
Increased by +N/A%
1.19 M
Increased by +117.37%
Increased by +2.35 K%
Decreased by N/A%
Dec 31, 23 73.60 K
Increased by +N/A%
-4.56 M
Increased by +33.64%
Decreased by -6.20 K%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-5.68 M
Increased by +1.08%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-5.68 M
Decreased by -19.09%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-6.87 M
Decreased by -18.67%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-6.87 M
Increased by +17.90%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY